TNF, tumor necrosis factor, 7124

N. diseases: 2724; N. variants: 31
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE It was further observed that pro-inflammatory cytokine like, TNF-α (Tumor Necrosis Factor-α) can antagonize TGF-β2-induced response by down-regulating autophagy, increasing ROS levels and thus inhibiting EMT in HCC cells. 29464083 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 GeneticVariation phenotype BEFREE Deletion of key genes within the tumor necrosis factor (TNF) signaling, interferon-γ (IFN-γ) signaling, and antigen presentation pathways provided protection of tumor cells from CD8<sup>+</sup> T cell-mediated killing and blunted antitumor immune responses in vivo. 29776993 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 AlteredExpression phenotype BEFREE Serum and peritoneal levels of vascular endothelial growth factor (VEGF), total antioxidant activity (TAC) and tumor necrosis (TNF)-α were measured. 30545536 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Autocrine tumor necrosis factor (TNF) signaling in the absence of TAK1 induced spontaneous RIPK1-dependent NLRP3 inflammasome activation and cell death. 29500178 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE IL-1β (Interleukin-1β) and TNF-α (Tumor Necrosis Factor-α) Impact Abdominal Aortic Aneurysm Formation by Differential Effects on Macrophage Polarization. 29217508 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE The concentrations of TNF-α (Tumor Necrosis Factor-α), IL-1β (Interleukin-1β), IL-6 and PGE-2 (Prostaglandin-E2) were evaluated using ELISA. 30014878 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 AlteredExpression phenotype BEFREE The main mechanism implicated in these beneficial effects were the inhibition of the downregulation of synaptophysin and its anti-inflammatory properties by means of preventing the upregulation of NF-κB and TNF-α (Tumor Necrosis Factor α) induced by diabetes. 30127248 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE The top four enriched pathways were the tumor necrosis factor (TNF) signaling pathway, P53 signaling pathway, neuroactive ligand‑receptor interaction and the forkhead box O signaling pathway. 29845294 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE The therapeutic response to biologics supports the pivotal role of the tumour necrosis alpha (TNF-?)/ interleukin (IL)-23/IL-17/IL-22 axis in the pathogenesis of these disorders. 28967976 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE LPS-mediated induction of Ccl17 in the hippocampus was dependent on local tumor necrosis factor (TNF) signaling, whereas upregulation of Ccl22 required granulocyte-macrophage colony-stimulating factor (GM-CSF). 30277599 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Notably, the transforming growth factor (TGF)‑β, mitogen‑activated protein kinase (MAPK) and tumor necrosis factor (TNF) signaling pathways were preferentially overrepresented in the Mg and LIPUS combination group, which was subsequently confirmed by reverse transcription‑quantitative polymerase chain reaction. 29767241 2018
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Analysis of tumor necrosis factor (TNF) signaling pathway which regulates the transcription factor Nuclear Factor κB (NF-κB) using this method identifies two types of incorrect cell decisions called false alarm and miss. 28379950 2017
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis indicated that these proteins mainly were involved in the process of cytokine-cytokine receptor interaction, transforming growth factor-β (TGF-β) signaling pathway, pathways in cancer, tumor necrosis factor (TNF) signaling pathway, and mitogen-activated protein kinase (MAPK) signaling pathway. 29344174 2017
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Signaling pathway analysis revealed that these DEGs were mainly involved in apoptosis, hypoxia‑inducible factor (HIF) 1a pathway, innate immune system, tumor necrosis factor (TNF) signaling pathway, cytokine‑cytokine receptor interaction, and other signal transduction pathways. 28944843 2017
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE 3xTg-AD mice had an increased pro-inflammatory response characterised by the production of pro-inflammatory mediators such as tumour necrosis TNF-α, IL-6, CCL5 and CXCL-1, as well as an increase in immune cell infiltration to the sites of infection. 28284226 2017
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE PubMed literature searches were conducted using combinations of search terms including ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, switch/switching, drug survival, and TNF/tumor necrosis factor to identify published articles with data on outcomes related to switching biologic therapies in patients with axSpA. 28551170 2017
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Tumor necrosis factor (TNF) signaling is required for inflammatory nociceptive (pain) sensitization in Drosophila and vertebrates. 28492538 2017
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 GeneticVariation phenotype BEFREE Chondrocytes from normal joint cartilage were cultured <i>in vitro</i> for interleukin 6 (IL6) or tumor necrosis factor (TNF) treatment and si-NR4A1 transfection, after which the possible mechanism involving NR4A1 was analyzed. 28337303 2017
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Tumor necrosis factor-α (TNF-α)-induced protein 8-like-2 (TNFAIP8L2 or TIPE2), a member of the tumor necrosis TNFAIP8 family, was found to be involved in the development and progression of several tumors. 28081733 2017
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 GeneticVariation phenotype BEFREE Interferon (IFN)γ release was evaluated by ELISA whereas cytokine profile [IFNγ, tumor necrosis (TNF)α, interleukin (IL)2] and phenotype (CD45RA, CCR7) by flow cytometry. 28837654 2017
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE In mouse monocytes, the lipopolysaccharide- (LPS-) induced tumor necrosis-<i>α</i> (TNF-<i>α</i>) synthesis was significantly inhibited by HNK and the MCP : HNK combination in a dose-dependent manner and synergistic effects were clearly demonstrated with the combination on TNF-<i>α</i> inhibition. 28900464 2017
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE Biologic therapy, such as those that target tumor necrosis factor (TNF) signaling, has proven to be an efficacious method of treatment for patients with inflammatory bowel disease (IBD) with regards to symptom management and mucosal healing. 28373759 2017
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE The tumor necrosis factor (TNF) signalling pathway was the most involved and preferentially inhibited by the hBCP material. 28942129 2017
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 Biomarker phenotype BEFREE TNF-α inhibition resulted in suppression of IL-6 and IL-8 in parallel with clinical improvement in all anti-TNF-treated subjects, but was also associated with elevated TNF-α and IL-17 in etanercept-treated subjects. 26934060 2016
CUI: C0333516
Disease: Tumor necrosis
Tumor necrosis
0.100 AlteredExpression phenotype BEFREE These humoral factors can generally be divided into those which, like RANKL, are tumour necrosis family (TNF) superfamily members and those which are not; the former include TNFα lymphotoxin exhibiting inducible expression and competing with herpes simplex virus glycoprotein D for herpesvirus entry mediator, a receptor expressed by T lymphocytes (LIGHT), a proliferation inducing ligand (APRIL) and B cell activating factor (BAFF); the latter include transforming growth factor beta (TGF-β), interleukin-6 (IL-6), IL-8, IL-11, nerve growth factor (NGF), insulin-like growth factor-I (IGF-I) and IGF-II. 26578261 2016